<SEC-DOCUMENT>0001640334-18-002397.txt : 20181219
<SEC-HEADER>0001640334-18-002397.hdr.sgml : 20181219
<ACCEPTANCE-DATETIME>20181219160112
ACCESSION NUMBER:		0001640334-18-002397
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20181214
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181219
DATE AS OF CHANGE:		20181219

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		181243499

	BUSINESS ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4
		BUSINESS PHONE:		250-765-6424

	MAIL ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lxrp_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html><head><title>lxrp_8k.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px">&nbsp; </p><b> <table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td> <div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div> <div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table> <p style="MARGIN: 0px">&nbsp;</p></b> <p style="MARGIN: 0px" align="center"><font size="3"><b>UNITED STATES </b></font></p> <p style="MARGIN: 0px" align="center"><font size="3"><b>SECURITIES AND EXCHANGE COMMISSION </b></font></p> <p style="MARGIN: 0px" align="center"><font size="3"><b>Washington, D.C. 20549</b></font></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b><font size="5">FORM 8-K</font></b></p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b>CURRENT REPORT</b></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px" align="center">Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px" align="center">Date of Report (Date of earliest event reported) <b><u>December 14, 2018</u></b></p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="60%" align="center" border="0"> <tr> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="74%" colspan="6"> <p style="MARGIN: 0px" align="center"><b><font size="5">LEXARIA BIOSCIENCE CORP.</font></b></p></td></tr> <tr> <td valign="top" width="74%" colspan="6"> <p style="MARGIN: 0px" align="center">(Exact name of registrant as specified in its charter)</p></td></tr></table>&nbsp;&nbsp;&nbsp; <p style="MARGIN: 0px"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="85%" align="center" border="0"> <tr height="15"> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Nevada</b></p></td> <td width="5%"> <p style="MARGIN: 0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b>000-52138&nbsp;</b></p></td> <td width="5%"> <p style="MARGIN: 0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="top" width="30%"> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b>20-2000871</b></p></td></tr> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">(State or other jurisdiction</p> <p style="MARGIN: 0px 0px 0px 0in" align="center">of incorporation)</p></td> <td> <p style="MARGIN: 0px">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">(Commission</p> <p style="MARGIN: 0px 0px 0px 0in" align="center">File Number)</p></td> <td> <p style="MARGIN: 0px">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="center">(IRS Employer</p> <p style="MARGIN: 0px 0px 0px 0in" align="center">Identification&nbsp;No.)</p></td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="85%" align="center" border="0"> <tr> <td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="45%" colspan="5"> <p style="MARGIN: 0px" align="center"><b>156 Valleyview Road, Kelowna, BC Canada </b></p></td> <td width="10%"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid" valign="bottom" width="45%"> <p style="MARGIN: 0px" align="center"><b>V1X 3M4</b></p></td></tr> <tr> <td valign="top" colspan="5"> <p style="MARGIN: 0px" align="center">(Address of principal executive offices)</p></td> <td> <p style="MARGIN: 0px" align="center">&nbsp;</p></td> <td valign="top"> <p style="MARGIN: 0px" align="center">(Zip Code)</p></td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px" align="center">Registrant&#8217;s telephone number, including area code <u><b>(250) 765-6424</b>&nbsp;</u></p> <p style="MARGIN: 0px" align="center">&nbsp;</p> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="74%" colspan="6"> <p style="MARGIN: 0px" align="center"><b><u>N/A</u></b></p></td></tr> <tr> <td valign="top" width="74%" colspan="6"> <p style="MARGIN: 0px" align="center">(Former name or former address, if changed since last report.)</p></td></tr></table>&nbsp; <p style="MARGIN: 0px 0px 0px 0in">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in"><font style="FONT-FAMILY: Wingdings">o </font>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p> <p style="MARGIN: 0px"><font style="FONT-FAMILY: Wingdings">o </font>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p> <p style="MARGIN: 0px"><font style="FONT-FAMILY: Wingdings">o </font>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&nbsp;CFR&nbsp;240.14d-2(b)) </p> <p style="MARGIN: 0px"><font style="FONT-FAMILY: Wingdings">o </font>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&nbsp;CFR&nbsp;240.13e-4(c)) </p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px" align="justify">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p> <p style="MARGIN: 0px" align="right">Emerging growth company <font style="FONT-FAMILY: Wingdings">o </font></p> <p style="MARGIN: 0px 0px 0px 1in; TEXT-INDENT: 0px">&nbsp;</p> <p style="MARGIN: 0px" align="justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <font style="FONT-FAMILY: Wingdings">o </font></p> <p style="MARGIN: 0px" align="left">&nbsp;</p> <p style="MARGIN: 0px" align="left"> <table style="FONT-SIZE: 1px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td> <div style="HEIGHT: 2px; WIDTH: 100%; BACKGROUND: #000000; MARGIN: 0px 0px 2px" name="hrule"></div> <div style="HEIGHT: 4px; WIDTH: 100%; BACKGROUND: #000000" name="hrule"></div></td></tr></table></p> <p style="MARGIN: 0px"> <table class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"><b>Item 3.02</b>&nbsp;<b>Unregistered Sales of Equity Securities</b>&nbsp;</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px" align="justify">On December 14, 2018 Lexaria announced an option award due to result of a filling a new staffing position. Lexaria is issued 30,000 stock options with an exercise price of US$1.16, that will vest as to 10,000 per year until April 15, 2021.</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px" align="justify"><b>The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.</b></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"><b>Item 7.01</b>&nbsp;<b>Regulation FD Disclosure</b>&nbsp;</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify">A copy of the news release announcing it has awarded a stock option to a newly hired employee is filed as exhibit 99.1 to this current report and is hereby incorporated by reference. </p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"><b>Item 9.01</b>&nbsp;<b>Financial Statements and Exhibits</b>&nbsp;</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr bgcolor="#cceeff"> <td valign="top" width="10%"> <p style="MARGIN: 0px"><a href="lxrp_ex991.htm">99.1</a></p></td> <td valign="top" width="90%"> <p style="MARGIN: 0px"><a href="lxrp_ex991.htm">Press Release dated December 14, 2018</a></p></td></tr></table>&nbsp;</p> <table id="pagebreak7e2578b5-8b1a-4706-8787-b5ff390a252a" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid"> <p style="MARGIN: 0px" align="center">2</p></td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px" align="center"><b>SIGNATURES</b></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr height="15"> <td valign="top" width="35%"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>LEXARIA BIOSCIENCE CORP.</b></p></td> <td> <p style="MARGIN: 0px">&nbsp;</p></td></tr> <tr height="15"> <td> <p style="MARGIN: 0px 0px 0px 0in" align="justify">&nbsp;</p></td> <td> <p style="MARGIN: 0px">&nbsp;</p></td></tr> <tr height="15"> <td style="BORDER-BOTTOM: 1px solid" valign="bottom"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><i>/s/ Chris Bunka</i></p></td> <td> <p style="MARGIN: 0px">&nbsp;</p></td></tr> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify"><b>Chris Bunka</b></p></td> <td> <p style="MARGIN: 0px">&nbsp;</p></td></tr> <tr height="15"> <td valign="top"> <p style="MARGIN: 0px 0px 0px 0in" align="justify">CEO, Principal Executive Officer</p></td> <td> <p style="MARGIN: 0px">&nbsp;</p></td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px">Date: December 19, 2018</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"> <table style="TEXT-ALIGN: justify; FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cols="1" cellpadding="0" width="100%" align="center" border="0"> <tr> <td style="BORDER-BOTTOM: black 1px solid"> <p style="MARGIN: 0px" align="center">3</p></td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p></BODY><!--Document Created by EDGARMaster--></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>lxrp_ex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head><title>lxrp_ex991.htm</title><!--Document Created by EDGARMaster--></head><BODY spellcheck="true" style="text-align:justify;font:10pt TIMES NEW ROMAN;margin:0px 7%"><p style="MARGIN: 0px" align="right"><b style="MARGIN: 0px">Exhibit 99.1</b></p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px 0px 0px 0in" align="center"><b>Lexaria Bioscience Issues Options</b></p> <p style="MARGIN: 0px 0px 0px 0in">&nbsp;</p> <p style="MARGIN: 0px" align="justify">Kelowna, British Columbia &#8211; December 14, 2018 &#8211; Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the &#8220;Company&#8221; or &#8220;Lexaria&#8221;), a drug delivery platform innovator, announces the following option award.</p> <p style="MARGIN: 0px" align="justify">As a result of a new staffing position being filled, Lexaria is issuing 30,000 stock options with an exercise price of US$1.16, that will vest as to 10,000 per year until April 15, 2021.</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px" align="justify"><b>The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.</b></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify"><b>About Lexaria</b></p> <p style="MARGIN: 0px" align="justify">Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has ten patents granted in the USA and in Australia and has filed over 50 patent applications worldwide across ten patent families. Lexaria&#8217;s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.</p> <p style="MARGIN: 0px" align="justify">www.lexariabioscience.com</p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px" align="justify"><img src="lxrp_ex991img1.jpg"> For regular updates, connect with Lexaria on Twitter <u>http://twitter.com/lexariacorp</u></p> <p style="MARGIN: 0px" align="justify"><img src="lxrp_ex991img2.jpg"> and on Facebook <u>http://www.facebook.com/lexariabioscience/</u></p> <p style="MARGIN: 0px" align="justify">&nbsp;</p> <p style="MARGIN: 0px">FOR FURTHER INFORMATION PLEASE CONTACT: </p> <p style="MARGIN: 0px">Lexaria Bioscience Corp. </p> <p style="MARGIN: 0px">Alex Blanchard, Communications Manager</p> <p style="MARGIN: 0px">(778) 796-1897</p> <p style="MARGIN: 0px">Or</p> <p style="MARGIN: 0px">NetworkNewsWire (NNW)</p> <p style="MARGIN: 0px">www.NetworkNewsWire.com</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"> <table id="pagebreakc8d9d40d-ece3-497c-9838-855b0fb87f79" class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid"> <p style="MARGIN: 0px" align="center">&nbsp;</p></td></tr> <tr> <td> <div style="WIDTH: 100%; PAGE-BREAK-AFTER: always; LINE-HEIGHT: 0px"></div>&nbsp;</td></tr> <tr> <td>&nbsp;</td></tr></table></p> <p style="MARGIN: 0px">&nbsp;&nbsp;</p> <p style="MARGIN: 0px">FORWARD-LOOKING STATEMENTS</p> <p style="MARGIN: 0px" align="justify">This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements, including but not limited to: that any additional stock warrants or stock options will be exercised. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that existing capital is sufficient for the Company's needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements; or that results from any studies will be favorable or in any way support future business activities of any kind. Scientific R&amp;D is often unpredictable and unanticipated results could emerge from any study and have a material impact as can any results that cannot be reproduced in subsequent testing. There is no assurance that any planned corporate activity, scientific study, R&amp;D, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria&#8217;s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). TurboCBD<sup>TM</sup>, DehydraTECH<sup>TM</sup> technology and ViPova<sup>TM</sup> products are not intended to diagnose, treat, cure or prevent any disease.</p> <p style="MARGIN: 0px">&nbsp;</p> <p style="MARGIN: 0px"><i>The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.</i></p> <p style="MARGIN: 0px"> <table class="pagebreak" style="FONT: 10pt TIMES NEW ROMAN" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td class="hpbhr">&nbsp;</td></tr> <tr> <td style="BORDER-BOTTOM: black 1px solid">&nbsp;</td></tr></table></p> <p style="MARGIN: 0px">&nbsp;</p></BODY><!--Document Created by EDGARMaster--></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>lxrp_ex991img1.jpg
<TEXT>
begin 644 lxrp_ex991img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  M "T# 2(  A$! Q$!_\0
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M<JW$^*IT.%\JS22AEZ52,JF&JXBG4Y:=?%8N%.=7#TZ[=&-+V;474EI_E?\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>lxrp_ex991img2.jpg
<TEXT>
begin 644 lxrp_ex991img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  M "T# 2(  A$! Q$!_\0
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-I7U4;ZMZ.3M?9'__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
